基于疫苗的免疫疗法和相关的临床前模型用于质瘤
Longping Yao1, Maryam Hatami1, Wenbin Ma2
1Institute for Anatomy and Cell Biology, Heidelberg Medical Faculty, Heidelberg University, Heidelberg, Germany.
Trends in molecular medicine
|July 16, 2024
概括
质瘤免疫疗法面临着挑战,特别是质母细胞瘤 (GBM). 瘤抗原向疫苗显示出有效的质瘤治疗的前景,特别是涉及CD4+T细胞.
科学领域:
- 神经瘤学神经瘤学
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 质瘤是最常见的原发性恶性脑瘤,质母细胞瘤 (GBM) 是最具攻击性的亚型.
- 尽管免疫疗法取得了进展,但GBM对当前治疗方法具有显著的耐药性.
- 向瘤抗原对于开发针对质瘤的有效免疫疗法至关重要.
研究的目的:
- 审查瘤疫苗用于质瘤治疗.
- 讨论临床前模型和CD4+ T细胞在疫苗诱导免疫中的作用.
- 总结临床策略,挑战和结质瘤免疫治疗的未来方向.
主要方法:
- 对质瘤疫苗和免疫疗法的现有文献的综述.
- 对质瘤免疫学研究的临床前模型的分析.
- 检查CD4+T细胞在抗质瘤免疫反应中的作用.
主要成果:
- 瘤抗原向策略正在加速对质瘤的免疫治疗的发展.
- 个性化疫苗,树突细胞 (DC) 疫苗和CAR/TCR T细胞显示出潜在的潜力.
- 最近的研究表明,对于GBM和低度质瘤 (LGG) 都有前景.
结论:
- 质瘤免疫疗法,特别是针对GBM的免疫疗法,仍然是一个重大挑战.
- 针对瘤抗原的基于疫苗的方法为未来的治疗提供了一个有希望的途径.
- 进一步研究CD4+T细胞的作用和临床策略对于提高疫苗疗效至关重要.
相关概念视频
Tumor Immunotherapy
504
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504
Cancer Vaccines
350
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
350


